Eighteen months of evolocumab therapy significantly reduced high-risk noncalcified plaque and microcalcification activity, suggesting its potential to stabilize coronary artery disease beyond cholesterol lowering.
Most Recent Articles
VISUALIZED: Innovative CMR Model Predicts Functional Heart Age in Healthy and High-Risk Populations
Read further: Innovative CMR Model Predicts Functional Heart Age in Healthy and High-Risk Populations
Genetic Adaptations in Haenyeo Divers: Insights into Blood Pressure Regulation and Cold Tolerance
Genetic analysis of Korea’s Haenyeo divers reveals adaptations that support lower blood pressure and cold tolerance—traits that may protect against hypertension and inform new treatments for cardiovascular and pain-related...
Cardiovascular Safety of JAKi in Rheumatoid Arthritis: A Multi-Country Real-World Study
An extensive international study finds that Janus kinase inhibitors do not increase cardiovascular risk compared to TNF inhibitors in rheumatoid arthritis patients, offering reassurance for short-term use across diverse...
Childhood Trauma and Its Impact on Substance Use and Cardiovascular Health in Adolescence: A Longitudinal Study in Brazil
A Brazilian cohort study links childhood trauma to increased adolescent substance use and unexpectedly lower heart rate and blood pressure, revealing complex pathways between early adversity and long-term cardiovascular health.